Immuron (IMRN) Income from Continuing Operations (2016 - 2025)
Immuron (IMRN) posted Income from Continuing Operations of -$3.3 million for Q2 2025, down 7126.84% on a QoQ basis from -$46223.4 in Q3 2024, and up 26.93% year-over-year from -$2.6 million in Q2 2024.
Powered by 
Analysis
Immuron (IMRN) Income from Continuing Operations (2016 - 2025) Analysis & Trends
Immuron has reported Income from Continuing Operations for 10 years, with the latest figure at -$3.3 million in Q2 2025.
- On a quarterly basis, Income from Continuing Operations rose 26.93% year-over-year to -$3.3 million in Q2 2025; TTM through Jun 2025 was -$10.4 million, a 20.81% decrease from a year earlier, with the FY2026 full-year figure at -$3.8 million, down 7207.34% from the prior year.
- Income from Continuing Operations was -$3.3 million for Q2 2025 at Immuron, down from -$46223.4 in the prior quarter.
- The five-year high for Income from Continuing Operations was -$13260.2 in Q4 2021, with the low at -$6.5 million in Q2 2021.
- Average Income from Continuing Operations over 5 years is -$2.3 million, with a median of -$1.9 million recorded in 2023.
- The sharpest annual moves came in 2021 and 2022: Income from Continuing Operations jumped 68.39% in 2021, then slumped 2558.11% in 2022.
- Over 5 years, Income from Continuing Operations stood at -$13260.2 in 2021, then plunged by 2558.11% to -$352470.5 in 2022, then tumbled by 599.34% to -$2.5 million in 2023, then jumped by 98.12% to -$46223.4 in 2024, then plunged by 7126.84% to -$3.3 million in 2025.
- The last three Income from Continuing Operations figures came in at -$3.3 million (Q2 2025), -$46223.4 (Q3 2024), and -$4.6 million (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -782.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 601.00 Mn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Immuron | 7.14 Mn | -1.88 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -3.34 Mn |
| Sep 9, 2024 | -46,223.37 |
| Jun 30, 2024 | -4.57 Mn |
| Dec 31, 2023 | -2.46 Mn |
| Jun 30, 2023 | -1.24 Mn |
| Dec 31, 2022 | -352,470.52 |
| Dec 31, 2021 | -13,260.17 |
| Jun 30, 2021 | -6.46 Mn |
| Dec 31, 2020 | -41,946.68 |
| Jun 30, 2020 | -1.92 Mn |
| Dec 31, 2019 | -15,212.27 |
| Dec 31, 2018 | -1.58 Mn |
| Dec 31, 2017 | 3.79 Mn |
| Dec 31, 2016 | 2.57 Mn |
| Jun 30, 2016 | -3.28 Mn |